#NACFC2021 – Trikafta Reduces Exacerbation Rate, Real-world Data Show

#NACFC2021 – Trikafta Reduces Exacerbation Rate, Real-world Data Show

311570

#NACFC2021 – Trikafta Reduces Exacerbation Rate, Real-world Data Show

Trikafta treatment can reduce the frequency of pulmonary exacerbations — times when lung symptoms get markedly worse — for people with cystic fibrosis (CF). That’s according to an analysis of real-world data shared at this year’s North American Cystic Fibrosis Conference (NACFC), in an oral presentation, “Impact of Elexacaftor/Tezacaftor/Ivacaftor (ETI) therapy use on pulmonary exacerbation rates during the COVID-19 pandemic.” Trikafta is an oral combination of three medications (elexacaftor, tezacaftor, and ivacaftor) that work to increase the…

You must be logged in to read/download the full post.